

Addendum

Following the circulation of the appeal letter a small number of errors were identified by two appellants. These errors do not affect the reasoning of the letter, which is published on the Institute's website in its original form. However, for completeness, the appropriate wording is set out below, with corrected errors underlined.

| Paragraph | Correction |
|------------|--|
| Throughout | References to the National Kidney Foundation should be read as references to the National Kidney <u>Federation</u> |
| 19 | Ms Fiona Loud represented the <u>British Kidney Patient Association</u> |
| 18 | <p>The third bullet point should read:</p> <ul style="list-style-type: none">• Tacrolimus is a calcineurin inhibitor. The Appraisal Committee considered preparations of immediate-release tacrolimus and of prolonged-release tacrolimus. Brands of immediate-release tacrolimus with marketing authorisations in the United Kingdom include Adoport (Sandoz), Capexion (Mylan), Perixis (Accord Healthcare), Tacni (Teva) and Vivadex (Dexcel Pharma). Astellas Pharma Ltd markets immediate-release tacrolimus as <u>Prograf and Modigraf</u> and prolonged-release tacrolimus as Advagraf. |
| 21 | <p>The final paragraph should read:</p> <p>The Appraisal Committee had excluded the studies of Silva and Albano, even though they included over twice as many patients, and even though they would have supported the conclusion that there was no difference in efficacy between the two formulations of <u>tacrolimus</u>.</p> |
| 31 | Malcolm Qualie, for NHS England, explained that <u>[wording deleted]</u> there was prescribing for stable patients in primary care. Because there were clinical concerns about switching brands, and because generic prescribing was common in primary care, NHS England had advised that all prescribing should now be in secondary care. |
| 47 | Professor McVeigh stated that liver transplant patients were different |

| | |
|--|---|
| | <p>from kidney transplant patients. He also pointed out that in the context of a complex regimen, a switch from <u>immediate</u>-release tacrolimus to <u>prolonged</u>-release tacrolimus would reduce the tablet count by only one.</p> |
|--|---|